News

Cardior Pharmaceuticals announced the CE marking of CardiorHealth miR-132 PCR kit which measures circulating microRNA-132 (miR-132) levels in the blood of heart failure patients following treatment with their lead candidate CDR132L. We are extremely proud that our biomarker assay development and manufacturing services have contributed to this success, and we look forward to continuing our cooperation.

Learn more

NADMED established the first ever CE marked IVD assay for measuring NAD metabolites in human blood. This is a huge step forward in the healthcare industry to help patients worldwide! We are extremely proud that our services have contributed to this success, and we look forward to continuing our cooperation.

Learn more

“Team Intelligence” behind Biotype’s Transformational Leadership

Transitioning into transformational leadership entails transformational changes. As Biotype is transforming and entering a new phase of development, it was vital for us to ensure that we decentralize decision making and adopt a more efficient approach.

Learn more

We are delighted to announce that Biotype is entering a new phase of its corporate development with the appointment of Dr. Norman Gerstner as new CEO and Dr. Felix Zörgiebel as new CTO succeeding Dr. Karim Tabiti effective April 1, 2022.

Learn more

07-10-2021
Biotype GmbH wins 1st place in the DNN Business Award 2020 offered by the Dresdner Neueste Nachrichten Verlag and the Ostsächsische Sparkasse Dresden.

Learn more

28-06-2021
Biotechnology and medical technology companies based in Saxony made a significant contribution to combating the corona pandemic.

Learn more

04-03-2021
New regulatory requirements are currently affecting the In-vitro diagnostic (IVD) industry with the transition from the In-vitro Diagnostic Directive (IVDD) to the In-vitro Diagnostic Regulation (IVDR).

Weiter lesen

05-12-2020
Biotype, together with a clinical cooperation partner, is right now developing a Modaplex panel to detect different genetic aberrations in one single run using synchronized PCR multiplex technologies.

Learn more

 

02-04-2020
Biotype GmbH is commissioned to produce components for the Corona Virus COVID-19 genesig® Real-Time PCR Test by Primerdesign Ltd. A daily capacity of 8,000 to 10,000 tests is planned.

Learn more

 

01-10-2019
Biotype launches 3 new assays on its molecular diagnostic platform ModaplexTM.

Learn more

 

28-06-2019
We are excited to announce that Biotype Diagnostic GmbH and Biotype Innovation GmbH have decided to merge their capabilities to form one strong entity.

Weiter lesen

 

07-02-2019
Biotype expands highly specific CE-IVD portfolio for chimerism monitoring. 56 Mentype® DIPquant assays are now CE-IVD-registered.

Weiter lesen

 

14-12-2018
Within the InfectControl 2020 FINAR BMBF-project the selection for resistances is captured for the first time systematically by specialists coming from the fields of phytopathology, veterinary medicine and infection biology. 

Learn more

 

13-12-2018
SYNLAB Pharma, a subsidiary of SYNLAB Holding Deutschland GmbH announces that it has signed a collaboration agreement with Biotype with the intention to offer a Europe-wide clinical trial service for MSI and POLE/POLD1 mutation detection to indicate if patients harboring from GI cancer or EC would benefit from immune checkpoint inhibitor therapy.

Learn more

 

01-06-2017
Since it was founded in 1999, Biotype Diagnostic GmbH has established an international position developing and marketing outstanding molecular diagnostics systems in the fields of forensics, dermatology and leukaemia. Another mainstay is producing complex testing systems commissioned by global players such as QIAGEN GmbH. Now, Biotype is extending its OEM business and exceptional skills in developing and producing made-to-order multiplex PCR assays in new fields.

Read more

 

14-03-2017
The new assays DigitalScreen/DigitalQuant of the Biotype Diagnostic GmbH ensure a robust and highly sensitive evaluation of disease progression after stem cell transplantation based on the innovative digital PCR technology.

Read more

 

23-02-2016
Quantitative Strategy for Chimerism Monitoring – new method provides significant increase in sensitivity by factor 20 which translates into massive time advantage

Read more
 

 

18-01-2016
50 molecular markers combined with highest sensitivity result in a dramatic improvement of chimerism monitoring

Read more